/00/$03.00/0 Vol. 141, No. 5
|
|
- David Jordan
- 6 years ago
- Views:
Transcription
1 /00/$03.00/0 Vol. 141, No. 5 Endocrinology Printed in U.S.A. Copyright 2000 by The Endocrine Society An Aged Rat Model of Partial Androgen Deficiency: Prevention of Both Loss of Bone and Lean Body Mass by Low-Dose Androgen Replacement* DIRK VANDERSCHUEREN, LIESBETH VANDENPUT, STEVEN BOONEN, ERIK VAN HERCK, JOHANNES V. SWINNEN, AND ROGER BOUILLON Laboratory for Experimental Medicine and Endocrinology (D.V., L.V., E.V.H., J.V.S., R.B.), Onderwijs en Navorsing, Gasthuisberg and Centre for Metabolic Bone Diseases (S.B.), Katholieke Universiteit Leuven, B-3000 Leuven, Belgium ABSTRACT The aim of this study was to evaluate the effects of different doses of androgen replacement, both on body composition and bone, in an aged male orchidectomized rat model. Testosterone was administered by 0.5, 1, and 2.5-cm sc SILASTIC implants (release of, respectively, 11.5, 23, and 55 g/day) to aged (12 months old, 550 g) male orchidectomized Wistar rats during a 15-week experimental period. T 0.5 only partially prevented decrease of ventral prostate and seminal vesicle weight, compared with an intact group that received an empty implant (Intact). The 1-cm implant (T 1) completely prevented decrease of both seminal vesicles and ventral prostate weight. The 2.5-cm implant (T 2.5) was clearly supraphysiological, as demonstrated by significant hypertrophy of both androgen-sensitive organs. Serum testosterone was lower in T 0.5 and T 1 ( ng/ml and ng/ml, respectively) and higher in T 2.5 ( ng/ml), compared with both Intact ( ng/ml) and the baseline group( ng/ml). As expected, orchidectomized rats that received an empty SILASTIC implant had significantly lower bone mineral content HYPOGONADAL MEN HAVE lower bone density (1), lower lean body mass (2), and higher bone turnover (3) than eugonadal men. In these men, androgen replacement increases lean body mass (2) and bone density (4, 5). However, in most human studies, androgen replacement is administered via im injection of testosterone enanthate, and these injections may lead (at least in the first days after the injection) to supraphysiological testosterone concentrations (6). Whether administration of lower doses of testosterone also protects against loss of bone and lean body mass remains to be clarified. This question is relevant because 20 30% of elderly men experience a relative deficiency of testosterone, compared with younger men (7), an observation commonly referred to as partial androgen deficiency of the aged male (PADAM) (8). In these elderly men, testosterone replacement Received October 15, Address all correspondence and requests for reprints to: D. Vanderschueren, Laboratory for Experimental Medicine and Endocrinology, Herestraat 49, B-3000 Leuven, Belgium. dirk.vanderschueren@ uz.kuleuven.ac.be. * The study was supported by the Flemish Fund for Scientific Research grant G and by a fellowship to Dr. Dirk Vanderschueren. Holder of the Merck Sharp & Dohme Chair in Metabolic Bone Diseases at the Katholieke Universiteit Leuven. Senior research assistant of the Fund for Scientific Research Flanders (Belgium). ( 7.9%), apparent density ( 5.7%), and lean body mass ( 10.8%), as measured by dual-energy x-ray absorptiometry, without significant changes in body weight and fat mass, compared with Intact. Also, cancellous ( 50.3%) and cortical ( 1.8%) volumetric density, as measured by peripheral quantitative computed tomography, were decreased in the tibia. Bone turnover, as measured by serum osteocalcin and urinary deoxypyridinoline excretion, was increased in orchidectomized rats that received an empty SILASTIC implant. T 0.5 prevented all changes, not only in bone mineral content, density, and turnover but also in lean body mass. Moreover, there were no significant differences, for all these parameters, between the different doses of testosterone replacement. In conclusion, low-dose androgen replacement does not lead to lower bone mineral density, higher bone turnover, and lower lean body mass in aged male rats, whereas complete androgen deficiency does. Therefore, the threshold concentration of testosterone necessary for prevention of both bone and lean body mass loss in aged male rats is clearly lower than for prostate and seminal vesicles. (Endocrinology 141: , 2000) should avoid supraphysiological concentrations of testosterone that may induce unwanted side effects such as polycythemia, sleep apnea syndrome, and (possibly) prostate hypertrophy (9). Studies in elderly men are also hampered by many concomitant diseases and medications that may affect both lean body mass, bone density, and androgen concentrations (10). The aim of this study was to evaluate the effects of different doses of androgen replacement on body composition and on bone in an aged male orchidectomized rat model. This model was characterized earlier as a representative model for bone studies of androgen replacement in hypogonadal men (11). Animals Materials and Methods Testosterone was administered by a 0.5-, 1-, or 2.5-cm sc SILASTIC brand implant (T 0.5, T 1, and T 2.5, respectively; Dow Corning, Midland, MI) in the cervical region to aged (12-month-old) male orchidectomized Wistar rats (n 10 for each group) during a 15-week experimental period. The effects of androgen replacement in these groups were compared with a group (n 10) of intact animals (Intact), orchidectomized animals (Orch, n 10) who received an empty SILASTIC implant, and a baseline (Base) group (n 10) that was killed at the beginning of the experimental period. All rats received a standard rat diet containing 0.4% calcium and 0.4% phosphate (Hope Farms, Woerden, The Neth- 1642
2 PARTIAL ANDROGEN DEFICIENCY 1643 erlands) and had free access to tap water. Animals were weighed regularly, and urine was collected the week before death, for measurement of deoxypyridinoline excretion, as described (12). Also before being killed, animals were anesthesized using Nembutal ip (60 mg/kg) (Sanofi Pharmaceuticals, Inc. Sante Animal, Brussels, Belgium) for in vivo measurement of lean body mass, bone mineral content (BMC), and density and fat mass, by dual-energy x-ray absorptiometry (DXA). After 15 weeks, the animals were killed under Nembutal anesthesia. Serum was collected from the abdominal aorta and stored at 20 C until measurement of testosterone, leptin, insulin-like growth factor I (IGF-I), cholesterol, and triglycerides. After sacrifice, ventral prostate and seminal vesicles were weighed. The left tibia was used for measurement of volumetric cancellous and cortical density and geometrics by peripheral quantitative computed tomography (pqct) ex vivo. The experiment was conducted after obtaining formal approval by the ethical committee of the Katholieke Universiteit Leuven. SILASTICS The in vitro release of testosterone from the SILASTIC tubes was calculated as follows: 1) Testosterone depots were prepared from polydimethylsilicone tubing (Silclear tubing, Degania Tubing, Degania, Israel, mm) of defined length (1 cm and 2 cm), which was filled with crystalline testosterone (Sigma, St. Louis, MO), sealed at both ends (Dow Corning Corp. Adhesive, type A, Dow Corning Corp.), and kept at room temperature for 24 h; 2) In a preliminary experiment, the in vitro release of the SILASTIC tubes was determined as follows: The SILASTIC tubes were incubated in a 50-ml solution containing 0.9% NaCl, 0.1% sodiumazide, 3% BSA,and 10 mm phosphate buffer, ph 7. Samples were removed at regular intervals and radioimmunoassayed for testosterone during a 15-day period. A linear release of testosterone in the buffer in function of time (r 0.98 for 1 cm and r 0.97 for 2 cm) was obtained. The SILASTIC release during 24 h in vitro was calculated to be 23 g for 1 cm and 44 g for 2 cm. Therefore, the daily dose of testosterone administered in vivo was 11.5 g in the T 0.5 group, 23 g inthe T 1 group, and 55 g in the T 2.5 group. Similar studies have demonstrated that implantation of SILASTIC tubes in orchidectomized rats clearly results in constant testosterone concentrations, both in short-term (13) and long-term (11) experiments. Assays Serum testosterone was measured by a commercial RIA kit (Biosource Technologies, Inc. Europe SA, Nivelles, Belgium). Intra and interassay variations were 4.7 and 8.1%, respectively. Serum leptin was measured by enzyme-linked immunosorbent assay (Assay Designs Inc., Ann Arbor, MI). Intra and interassay variations were 4.8 and 3.5%, respectively. Serum osteocalcin and IGF-I were measured by in-house RIA, as described (14, 15). Urinary deoxypyridinoline (DPD) excretion was measured by HPLC, as described previously (12). Serum cholesterol and triglycerides were measured on a Roche Molecular Biochemicals (Mannheim, Germany) Hitachi 747 automated chemical analyzer. DXA of the whole skeleton, femur, and lumbar vertebrae Total BMC, area, density, lean body mass, and fat mass were measured in vivo by QDR 4500A fan beam x-ray bone densitometer (Hologic, Inc.,Waltham, MA) using a specific software program from the manufacturer for rats weighing g. The BMC and apparent bone mineral density (BMD) of the whole body skeleton (software version v8.19a), lumbar spine (scanned at the levels of the vertebrae L 1 -L 2 -L 3 -L 4 ; regional high resolution, software version v8.16h), and femur (regional high resolution, software version v8.16h) were determined. pqct of the left proximal tibia The defatted tibia was placed in a specially constructed vial containing 70% ethanol and mounted in the Stratec XCT 960A densitometer (Norland Medical Systems, Inc., Fort Atkinson, WI) with a special support. Two CT-slices of each 1 mm of thickness were obtained using a voxel size of mm. Volumetric cancellous bone density was calculated on a slice at 5 mm proximal from the knee joint. Volumetric cortical bone density was measured on a second slice 15 mm from the knee joint. Volumetric cancellous bone density has been calculated using contmode 1, peel-mode 20, and threshold 530, whereas, for cortical bone, contmode 1 and threshold 930 were used. Endocortical and periosteal perimeter represent, respectively, the length of the inner and outer perimeters of the second slice and are expressed in mm. We have previously found that the coefficient of variation of these measurements is 4.2% for trabecular bone and 0.72% for cortical bone. Statistical analysis Data analysis was performed with a software program (NCSS 2000, Kaysville, UT). The results are presented as mean sem. One-way ANOVA was carried out to detect overall differences and if P was less than 0.05, was followed by Fisher s least-significant-difference multiplecomparison test to calculate intergroup differences vs. Intact, Orch, and Base. The Pearson product-moment test was used for the measurement of the correlations. Results Serum testosterone concentrations and ventral prostate and seminal vesicle wet weight As expected, serum testosterone (Fig. 1a) ventral prostate weight (Fig. 1b) and seminal vesicles weight (Fig. 1c) decreased in the Orch group. Serum testosterone was lower in the T 0.5 and T 1 groups and higher in the T 2.5 group, compared with Intact. T 0.5 only partially prevented this decrease of ventral prostate and seminal vesicle weight ( 45 and 52%, respectively), compared with Intact. The 1-cm implant completely prevented the decrease of both seminal vesicle and ventral prostate weight. The 2.5-cm implant was clearly supraphysiological, as demonstrated by significant hypertrophy of both androgen-sensitive organs, compared with Intact. Ventral prostate weight and seminal vesicle weight were significantly higher in T 0.5, T 1, and T 2.5, compared with Orch. Biochemical parameters Serum osteocalcin and urinary DPD increased in the Orch group (Table 1). The T 0.5 group had similar, and thet1and T 2.5 groups had lower osteocalcin concentrations than Intact. All three doses of testosterone replacement, however, significantly reduced serum osteocalcin concentrations, compared with Orch. Also, DPD excretions in the groups with different doses of androgen replacement were significantly lower than in Orch. Urinary DPD in the T 0.5 group, however, remained significantly higher than in Intact. No significant changes in serum lipids, IGF-I, or leptin were observed. As expected, serum leptin was significantly correlated with fat mass (r 0.68, P 0.001) and serum triglycerides (r 0.29, P 0.05). BMC and density of the whole skeleton, as measured by DXA Orch rats had significantly lower BMC (Fig. 2a) and BMD (Fig. 2b), compared with both Intact and Base. Testosterone administration to orchidectomized animals prevented this decrease of BMC and BMD. There were no significant differences between the groups with different doses of androgen replacement, with respect to BMC and BMD.
3 1644 PARTIAL ANDROGEN DEFICIENCY Endo 2000 Vol 141 No 5 Only the T 2.5 group had greater endocortical and periosteal perimeters without gain in cortical thickness, compared with Intact. Cancellous density was lower in Intact, compared with Base. Both cortical and cancellous density of the left tibia were significantly decreased in Orch, compared with Intact. Again, even the lowest dose of testosterone (T 0.5) corrected the density to Intact levels. Administration of higher doses of testosterone did not increase cancellous bone density. Body weight, lean body mass, and fat mass, as measured by DXA Body weight (Table 1) and fat mass (Fig. 2c) were not significantly different between the groups, except for a lower fat mass at baseline. Orch rats had lower lean body mass (Fig. 2d). Lean body mass increased after androgen replacement and was not different between the T 0.5, T 1, and T 2.5 groups and the Intact group. Moreover, lean body mass and BMC were significantly correlated (r 0.54, P ). FIG. 1. Serum testosterone concentration (1a), ventral prostate weight (1b), and seminal vesicles weight (1c) in the Base group, the Intact group, the orchidectomized group without testosterone replacement (Orch), and the orchidectomized groups treated with testosterone (T 0.5, T 1, and T 2.5). Statistical analysis: one-way ANOVA was carried out to detect overall differences and, if P was less than 0.05, was followed by Fisher s least significant difference (LSD) multiple-comparison test., P 0.05, compared with Base; *, P 0.05, compared with Intact;, P 0.05, compared with Orch; NA, not available. BMC and density of the distal lumbar vertebrae and femur, as measured by DXA Again, both BMC and BMD were decreased in Orch rats (Table 2), and androgen replacement in orchidectomized animals prevented bone loss. Differences between the groups with different doses of androgen replacement were not significant. Bone structure, and cancellous and cortical density of the left tibia, as measured by pqct The Intact group had thinner cortices, compared with Base, because of a greater endocortical perimeter (Table 2). Discussion The aged orchidectomized rat was used as an animal model to address the critically important question of the threshold serum concentration of testosterone needed to maintain BMC, density, and lean body mass in aging men. According to earlier work, this model reflects very well the skeletal effects of androgen deficiency and replacement in hypogonadal men (11). However, the skeletal effects of lower- and higher-than physiological doses of testosterone were not yet evaluated in this model. Therefore, in this study, we evaluated both skeletal effects and effects on lean body mass of different doses of testosterone in the aged orchidectomized rat. Assuming that a daily production of 5000 g in adult men (16) would correspond with a daily production of about 30 g in a 500-g rat, the 1-cm SILASTIC implant (23 g/day) would probably correspond with the low physiological range in men. Indeed, serum testosterone concentrations in this group were lower than in Intact. However, seminal vesicle wet weight and ventral prostate weight were not decreased, compared with Intact, suggesting that low serum testosterone concentrations are still sufficient to maintain intact ventral prostate and seminal vesicles weight. Serum testosterone concentrations in the group that received the 0.5-cm implant were only 25% of intact levels. This dose of androgen replacement was clearly subphysiological, as indicated by ventral prostate weight and seminal vesicle wet weight that were, respectively, 45 and 52% lower than in Intact. Serum testosterone concentrations in the T 2, 5 group, finally, were supraphysiological, as evidenced by significant hypertrophy of both androgen-sensitive organs. The 1-cm testosterone implant prevented both the increase of bone turnover and the decrease of bone mass and lean body mass. However, contrary to our expectations, low-dose androgen replacement also prevented both the increase of bone turnover and the decrease of bone mass and lean body mass. Therefore, threshold serum concentrations of testosterone of only 25% of Intact are already sufficient to prevent the loss of bone
4 PARTIAL ANDROGEN DEFICIENCY 1645 TABLE 1. General data Base Intact Orch T 0.5 T 1 T 2.5 P value (ANOVA) Body weight (g) NS Serum IGF-I (ng/ml) NS Serum total cholesterol (mg/dl) NS Serum HDL cholesterol (mg/dl) NS Serum triglyceride (mg/dl) NS Serum leptin (ng/ml) NS Serum osteocalcin (ng/ml) a,b 73 2 c 60 4 b,c 58 3 a,b,c Urinary deoxypyridinoline ( M/mM creat) a,b 36 2 b,c 31 2 c 26 2 c Statistical analysis: one-way ANOVA was carried out to detect overall differences, and if P 0.05 was followed by Fisher LSD multiplecomparison test. Date are reported as mean SEM for baseline (Base) and, at the end of the experimental period, in control rats (Intact), orchidectomized rats (Orch), and orchidectomized rats treated with testosterone (T 0.5, T 1, and T 2.5). Baseline data are indicated in italics. HDL, High-density lipoprotein; NS, not significant. a P 0.05, compared with Base. b P 0.05, compared with Intact. c P 0.05, compared with Orch. FIG. 2. BMC (2a), BMD (2b), fat mass (2c), and lean body mass (2d) in the Base group, the Intact group, the orchidectomized group without testosterone replacement (Orch), and the orchidectomized groups treated with testosterone (T 0.5, T 1, and T 2.5), as measured by DXA. Statistical analysis: one-way ANOVA was carried out to detect overall differences and, if P was less than 0.05, was followed by Fisher s LSD multiple-comparison test., P 0.05, compared with Base; *, P 0.05, compared with Intact;, P 0.05, compared with Orch. and lean body mass in this model. Serum osteocalcin concentrations in the rats that received 1-cm and 2.5-cm testosterone implants were even lower than in Intact, suggesting that the major effect of testosterone is to reduce bone resorption, rather than to stimulate bone formation. Overall, the effects of supraphysiological administration of testosterone were not more beneficial than the effects of physiological administration on either lean body mass or bone mass. However, the increase of periosteal perimeter, compensated by an increase of endosteal perimeter, suggests that testosterone in supraphysiological concentration may also stimulate periosteal bone formation. Translation of these animal data to humans would have important implications for androgen deficiency and replacement: First, PADAM, (which corresponds to the T 0.5 implant in this study) should be regarded as a distinct condition from overt hypogonadism (which corresponds to the Orch group in this study). The effects of PADAM on androgen target organs, such as bone and lean body mass, may be not as important as the well-established detrimental effects of overt hypogonadism (1, 2). Moreover, it follows that whether the beneficial effects of androgen replacement observed in hypogonadal men also apply to men suffering from PADAM can only be determined by properly designed randomized
5 1646 PARTIAL ANDROGEN DEFICIENCY Endo 2000 Vol 141 No 5 TABLE 2. Bone mineral content and density of the distal lumbar vertebrae and femur as measured by DXA; bone structure and bone densities of the tibia as measured by pqct P value (ANOVA) Base Intact Orch T 0.5 T 1 T 2.5 Distal lumbar vertebrae BMC (g) a,b c c c 0.05 BMD (g/cm 2 ) a,b c c c 0.01 Total femur BMC (g) a c c c 0.05 BMD (g/cm 2 ) a,b c c c 0.05 Tibia Periosteal perimeter (mm) c a,b,c 0.01 Endocortical perimeter (mm) a a,b,c 0.01 Cortical thickness (mm) a a a a a 0.05 Cancellous volumetric density (g/cm 3 ) a a,b a,c a,c a,c 0.01 Cortical volumetric density (g/cm 3 ) a a,b a,c c a 0.01 Statistical analysis: one-way ANOVA was carried out to detect overall differences, and if P 0.05 was followed by Fisher LSD multiple-comparison test. Data are reported as mean SEM for baseline (Base) and, at the end of the experimental period, in control rats (Intact), orchidectomized rats (Orch), and orchidectomized rats treated with testosterone (T 0.5, T 1, and T 2.5). Baseline data are indicated in italics. a P 0.05, compared with Base. b P 0.05, compared with Intact. c P 0.05, compared with Orch. clinical trials in PADAM-patients. Thusfar, only a few shortterm studies, including only a small number of elderly men, were reported, without detailed assessment of the effects of androgen replacement on bone (17 19). Similarly, the clinical impact of androgen replacement on lean body mass and body composition in partially androgen-deficient men remains to be clarified (8). In agreement with our data, a recent randomized controlled study in elderly men with only partial androgen deficiency could find no overall significant beneficial effect of androgen replacement on bone density and turnover (20). Only those men with the lowest testosterone concentrations seemed to benefit from androgen replacement. Second, supraphysiological replacement in humans may lead to changes in serum lipids or induce unwanted side effects, such as prostate hypertrophy, polycythemia, or sleep apnea syndrome (9). In this study, supraphysiological replacement (which corresponds to the T 2.5 implant) had no effects on serum lipids or high-density lipoprotein cholesterol, which is in contrast with some studies in men (19, 21). The modest muscle hypertrophy observed in healthy exercising eugonadal men receiving supraphysiological doses of testosterone (22) may not be relevant for either our animal model or the elderly male. Despite these side effects, there was no real benefit on bone or lean body mass, which suggests that there is no indication for supraphysiological androgen replacement in hypogonadal men. Third, a very close correlation between responses in bone and lean body mass to testosterone replacement are also in line with earlier data published in hypogonadal men (5). This may indicate that the positive effect of testosterone therapy on bone depends, in part, on its effects on muscle. Whether the effects of testosterone depend on stimulation of androgen receptors, or estrogen receptors after aromatization of testosterone in bone or muscle, is unknown. It is, however, unlikely that the effects of testosterone are related to changes in serum IGF-I concentrations (which were not different between groups in this study). In conclusion, continuous administration of a low dose of testosterone, a dose that was clearly not able to maintain prostate and seminal vesicles weight, prevented loss of both bone and lean body mass in an aged male orchidectomized animal model. Therefore, it would be interesting to investigate whether a similar low-dose replacement of testosterone would have similar effects in hypogonadal men. Acknowledgments The authors thank Herman Borghs, Jos Nijs, and Herman Peeters for expert technical assistance. References 1. Finkelstein JS 1998 Androgens and bone metabolism. In: Nieschlag E, Behre HM (eds) Testosterone. Action-Deficiency-Substitution. Springer-Verlag, Berlin-Heidelberg-New York, pp Brodsky IG, Balagopal P, Nair KS 1996 Effects of testosterone replacement on muscle mass and muscle protein synthesis in hypogonadal men: a Clinical Research Center study. J Clin Endocrinol Metab 81: Stepan JJ, Lachman M, Zverina J, Pacovsky V, Baylink DJ 1989 Castrated men exhibit bone loss: effect of calcitonin treatment on biochemical indices of bone remodeling. J Clin Endocrinol Metab 69: Behre HM, Kliesch S, Leifke E, Link TM, Nieschlag E 1997 Long-term effect
6 PARTIAL ANDROGEN DEFICIENCY 1647 of testosterone therapy on bone mineral density in hypogonadal men. J Clin Endocrinol Metab 82: Katznelson L, Finkelstein JS, Schoenfeld DA, Rosenthal DI, Anderson EJ, Klibanski A 1996 Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J Clin Endocrinol Metab 81: Snyder PJ, Lawrence DA 1980 Treatment of male hypogonadism with testosterone enanthate. J Clin Endocrinol Metab 51: Vermeulen A 1991 Androgens in the aging male - clinical review 24. J Clin Endocrinol Metab 73: Kaufman JM, Vermeulen A 1998 Androgens in male senescence. In: Nieschlag E, Behre HM (eds) Testosterone. Action-Deficiency-Substitution. Springer- Verlag, Berlin-Heidelberg-New York, pp Nieschlag E, Behre HM 1998 Pharmacology and clinical uses of testosterone. In: Nieschlag E, Behre HM (eds) Testosterone. Action-Deficiency-Substitution. Springer-Verlag, Berlin-Heidelberg-New York, pp Tenover JS 1992 Effect of testosterone supplementation in the aging male. J Clin Endocrinol Metab 75: Vanderschueren D, Van Herck E, Suiker AMH, Visser WJ, Schot LPC, Bouillon R 1992 Bone and mineral metabolism in aged male rats: short- and long-term effects of androgen deficiency. Endocrinology 130: Vanderschueren D, Jans I, Van Herck E, Moermans K, Verhaeghe J, Bouillon R 1994 Time-related increase of biochemical markers of bone turnover in androgen-deficient male rats. Bone Miner 26: Marchetti B, Poulin R, Plante M, Labrie F 1988 Castration levels of plasma testosterone have potent stimulatory effects on androgen-sensitive parameters in the rat prostate. J Steroid Biochem 31: Verhaeghe J, Van Herck E, Van Bree R, Van Assche FA, Bouillon R 1989 Osteocalcin during the reproductive cycle in normal and diabetic rats. J Endocrinol 120: Verhaeghe J, Van Herck E, Visser WJ, Suiker AMH, Thomasset M, Einhorn TA, Faierman E, Bouillon R 1990 Bone and mineral metabolism in BB rats with long-term diabetes. Decreased bone turnover and osteoporosis. Diabetes 39: Mooradian AD, Morley JE, Korenman SG 1987 Biological actions of androgens. Endocr Rev 8: Urban RJ, Bodenburg Y, Gilkison C, Foxworth J, Coggan AR, Wolfe RR, Ferrando A 1995 Testosterone administration to elderly men increases skeletal muscle strength and protein synthesis. Am J Physiol 269:E820 E Morley JE, Perry HM, Kaiser FE, Kraenzle D, Jensen J, Houston K, Mattamel M 1993 Effects of testosterone replacement therapy in old hypogonadal males: a preliminary study. J Am Geriatr Soc 41: Sih R, Morley JE, Kaiser FE, Perry III HM, Patrick P, Ross C 1997 Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial. J Clin Endocrinol Metab 82: Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh L, Holmes JH, Dlewati A, Staley J, Santanna J, Kapoor SC, Attie MF, Haddad Jr JG, Strom BL 1999 Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab 84: von Eckardstein A 1998 Androgens, cardiovascular risk factors and atherosclerosis. In: Nieschlag E, Behre HM (eds) Androgens. Action-Deficiency- Substitution. Springer-Verlag, Berlin-Heidelberg-New York, pp Bhasin S, Storer TW, Berman N, Callegari C, Clevenger BA, Philips J, Bunnell T, Tricker R, Shirazi A, Casaburi R 1996 The effects of supraphysiologic doses of testosterone on muscle size and strength in men. N Engl J Med 335:1 7
Testosterone Hormone Replacement Drug Class Prior Authorization Protocol
Testosterone Hormone Replacement Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective date: April 1, 2018 This policy has been developed through
More informationDrug Class Monograph
Drug Class Monograph Class: Testosterone Hormone Replacement Drug: Androderm (testosterone transdermal system), Androgel (testosterone topical gel), Axiron (testosterone topical solution), Aveed (testosterone
More informationDonald W. Morrish, MD, PhD, FRCPC Presented at Mountain Man: Men's Health Conference, May Terry s Testosterone
Focus on CME at University of Alberta ADAM: Dealing with the Decline Donald W. Morrish, MD, PhD, FRCPC Presented at Mountain Man: Men's Health Conference, May 2005 We now know there is a decline in total
More informationTestosterone Hormone Replacement Drug Class Prior Authorization Protocol
Line of business: Medi-Cal Effective Date: August 16, 2017 Revision Date: August 16, 2017 Testosterone Hormone Replacement Drug Class Prior Authorization Protocol This policy has been developed through
More informationChapter 5. General discussion
Chapter 5. General discussion 127 Chapter 5 In 2003, two review papers concluded that endogenous androgens do not show any consistent association with cardiovascular disease (CVD) risk 1,2. Apparently,
More informationThe use of testosterone is increasing in middle-aged and
JCEM ONLINE Brief Report Endocrine Care A Randomized Pilot Study of ly Cycled Testosterone Replacement or Testosterone Replacement Versus Placebo in Older Men Melinda Sheffield-Moore,* E. Lichar Dillon,*
More informationTESTOFEN HUMAN CLINICAL TRIAL GENCOR PACIFIC, INC. Copyright 2006 by Gencor Pacific, Inc.
GENCOR PACIFIC, INC. 920 E. Orangethorpe Avenue, Suite B, Anaheim, CA 92801 Ph: 714.870.8723 714.870.8724 efax: 732.875.0306 drjit@gencorpacific.com gita@gencorpacific.com www.gencorpacific.com TESTOFEN
More informationSELECT WHEY SOME THOUGHTS ON WHY WHEY PROTEIN CONTINUES TO BE CLINICALLY IMPORTANT
SELECT WHEY SOME THOUGHTS ON WHY WHEY PROTEIN CONTINUES TO BE CLINICALLY IMPORTANT Certainly, a legitimate concern about whey protein supplementation is allergenicity. However, while this concern is warranted,
More informationMedical Policy Testosterone Therapy
Medical Policy Testosterone Therapy Subject: Testosterone Therapy Effective Date: April 2015 Overview: Testosterone cypionate, testosterone enanthate, testosterone undecanoate, and testosterone pellet
More informationTESTOFEN. Anabolic & Androgenic Activity GENCOR PACIFIC, INC. Fenugreek Extract standardized for FENUSIDE TM. Copyright 2005 by Gencor Pacific, Inc.
GENCOR PACIFIC, INC. 920E. Orangethorpe Avenue, Suite B, Anaheim, CA. 92801 Ph: 714.870.8723 714.870.8724 efax: 732.875.0306 drjit@gencorpacific.com manu@gencorpacific.com www.gencorpacific.com TESTOFEN
More informationGrowth Hormone & Somatotropin are an Ergogenic Aid
Growth Hormone & Somatotropin are an Ergogenic Aid BPK 312 MARCH 28 2017 MICHAEL MORKOS PAUL SOURIAL DEL INGVALDSON Table of Contents 1. Hypothesis 2. Clinical Use 3. Mechanism of Action 4. Growth hormone
More informationOriginal Research Declining testicular function in aging men
(2003) 15, Suppl 4, S3 S8 & 2003 Nature Publishing Group All rights reserved 0955-9930/03 $25.00 www.nature.com/ijir Original Research 1 * 1 Wesley Woods Health Center, Atlanta, Georgia, USA Age-related
More informationIssues. What is a low testosterone? Who needs testosterone therapy? Benefits/adverse effects of testosterone replacement Treatment options
Male Hypogonadism Jauch Symposium Waterloo, IA May 17, 2013 Janet A. Schlechte, M.D. Disclosure of Financial Relationships Janet A. Schlechte, M.D. has no relationships with any proprietary entity producing
More informationRelationship between Aerobic Training and Testosterone Levels in Male Athletes
Relationship between Aerobic Training and Testosterone Levels in Male Athletes Siu Yuen Ng Biology 493 13 th December, 2010 Abstract Salivary testosterone levels of 11 athletes and 15 non athletes were
More informationThe ICL Insider. Lab Testing: Testosterone. In This Issue. The Debate
The ICL Insider February 2017 Volume 2, Issue 2 Lab Testing: Testosterone In This Issue Testosterone shashtilak@iclabs.ca Next Issue: Expected Release April 2017 The Debate Aging is accompanied by various
More informationInsight into male menopause'
Insight into male menopause' Dr Mark Vanderpump MD FRCP Consultant Endocrinologist Clinics: Tuesday PM Mark Vanderpump Consultant Physician and Endocrinologist Introduction Serum total and free testosterone
More informationTestosterone Use and Effects
Parkland College Natural Sciences Poster Sessions Student Works 2013 Testosterone Use and Effects Brandon Mills Parkland College Recommended Citation Mills, Brandon, "Testosterone Use and Effects" (2013).
More informationTranssexuals and competitive sports
European Journal of Endocrinology (2004) 151 425 429 ISSN 0804-4643 REVIEW Transsexuals and competitive sports Louis J G Gooren and Mathijs C M Bunck Department of Endocrinology, Section of Andrology,
More informationCurrent Data and Considerations Novel Testosterone Formulations
Current Data and Considerations Novel Testosterone Formulations 1 Current and Novel Therapeutic Options Module 4 2 Objectives Identify desirable characteristics of ideal testosterone formulations Review
More informationTestosterone administration to older men improves muscle function: molecular and physiological mechanisms
Am J Physiol Endocrinol Metab 282: E60 E607, 2002. First published November ; 0.52/ajpendo.0062.200. Testosterone administration to older men improves muscle function: molecular and physiological mechanisms
More informationSecrets of Abang Sado : Effects of testosterone therapy. Azraai Nasruddin
+ Secrets of Abang Sado : Effects of testosterone therapy Azraai Nasruddin + Testosterone Testosterone : Steroid hormone - Made primarily by the testicles in males - Small amounts produced by the adrenal
More informationUse of biotechnology to improve muscle growth in aquaculture species: Preliminary results on the use of myostatin in tilapia
Nov. 12, 2011 HAAA Workshop Use of biotechnology to improve muscle growth in aquaculture species: Preliminary results on the use of myostatin in tilapia Yong Soo Kim, PhD Department of Human Nutrition,
More informationANDROGENS PLAY AN essential role in the sexual
0021-972X/04/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 89(11):5429 5434 Printed in U.S.A. Copyright 2004 by The Endocrine Society doi: 10.1210/jc.2004-0897 Intramuscular Testosterone
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2018-9 Program Prior Authorization/Medical Necessity Topical Androgens Medication Axiron*, Androderm, Androgel*, Fortesta*, Natesto*,
More informationX/00/$03.00/0 Vol. 85, No. 8 The Journal of Clinical Endocrinology & Metabolism. Printed in U.S.A. Copyright 2000 by The Endocrine Society
0021-972X/00/$03.00/0 Vol. 85, No. 8 The Journal of Clinical Endocrinology & Metabolism rinted in U.S.A. Copyright 2000 by The Endocrine Society Effects of Testosterone Replacement in Hypogonadal Men*
More informationMonth/Year of Review: September 2013 Date of Last Review: December 2009
Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119 Copyright 2013 Oregon State University. All Rights
More informationThe New England Journal of Medicine
The New England Journal of Medicine Copyright, 1996, by the Massachusetts Medical Society VOLUME 335 J ULY 4, 1996 NUMBER 1 THE EFFECTS OF SUPRAPHYSIOLOGIC DOSES OF TESTOSTERONE ON MUSCLE SIZE AND STRENGTH
More informationJeremiah Murphy, MD Mercy Urology Clinic. October 21, 2017
Jeremiah Murphy, MD Mercy Urology Clinic October 21, 2017 Describe an appropriate strategy for the evaluation and diagnosis of male hypogonadism Endocrine Society Clinical Practice Guideline-2010 Review
More informationHARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES
Generic Brand HICL GCN Exception/Other METHYL ANDROID METHITEST METHYL TESTRED 01404 ROUTE MISCELL. CYPIONATE ENANTHATE GUIDELINES FOR USE ANDRODERM ANDROGEL AXIRON FORTESTA NATESTO STRIANT TESTIM VOGELXO
More informationReproductive DHT Analyte Information
Reproductive DHT Analyte Information - 1 - DHT Introduction Dihydrotestosterone (DHT) together with other important steroid hormones such as testosterone, androstenedione (ASD) and dehydroepiandrosterone
More informationPRODUCT INFORMATION TESTOVIRON DEPOT. (testosterone enanthate)
PRODUCT INFORMATION TESTOVIRON DEPOT (testosterone enanthate) NAME OF THE MEDICINE Testosterone enanthate is designated chemically as 17 beta-heptanoyloxy-4-androstene-3- one. The empirical formula of
More informationRobert Perlstein, M.D. Medical Officer. Center for Drug Evaluation and Research. U.S. Food & Drug Administration
-------------------- Robert Perlstein, M.D. Medical Officer Center for Drug Evaluation and Research U.S. Food & Drug Administration -------------------- Sentencing of Food and Drug Offenses Before the
More informationGonadal Steroids and Body Composition, Strength, and Sexual Function in Men
T h e n e w e ngl a nd j o u r na l o f m e dic i n e original article Gonadal Steroids and Body Composition, Strength, and Sexual Function in Men Joel S. Finkelstein, M.D., Hang Lee, Ph.D., Sherri-Ann
More informationTHE INFLUENCE OF SLOW RECOVERY INSOLE ON PLANTAR PRESSURE AND CONTACT AREA DURING WALKING
March 12, 2015 5:39:44pm WSPC/170-JMMB 1540005 ISSN: 0219-51942nd Reading Journal of Mechanics in Medicine and Biology Vol. 15, No. 2 (2015) 1540005 (6 pages) c World Scientific Publishing Company DOI:
More informationM0BCore Safety Profile. Pharmaceutical form(s)/strength: 5 mg SE/H/PSUR/0002/006 Date of FAR:
M0BCore Safety Profile Active substance: Finasteride Pharmaceutical form(s)/strength: 5 mg P-RMS: SE/H/PSUR/0002/006 Date of FAR: 16.05.2014 4.3 Contraindications Finasteride is not indicated for use in
More informationInhibition of 5-alpha reductase blocks prostate effects of testosterone without
Articles in PresS. Am J Physiol Endocrinol Metab (September 14, 2004). doi:10.1152/ajpendo.00305.2004 Borst et al. E-00305-2004.R1-1 Inhibition of 5-alpha reductase blocks prostate effects of testosterone
More informationAndrogens and Anabolic Steroids Prior Authorization with Quantity Limit - Through Preferred Topical Androgen Agent
Androgens and Anabolic Steroids Prior Authorization with Quantity Limit - Through Preferred Topical Androgen Agent Androgens/Anabolic Steroids Prior Authorization with Quantity Limit Through Preferred
More informationOF THE one thousand generations of humans that have
0021-972X/98/$03.00/0 Vol. 83, No. 10 Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright 1998 by The Endocrine Society THERAPEUTIC PERSPECTIVE Issues in Testosterone Replacement
More informationTestosterone dose-response relationships in healthy young men
Am J Physiol Endocrinol Metab 281: E1172 E1181, 2001. dose-response relationships in healthy young men SHALENDER BHASIN, 1 LINDA WOODHOUSE, 1 RICHARD CASABURI, 3 ATAM B. SINGH, 1 DIMPLE BHASIN, 3 NANCY
More informationMALE HORMONE THERAPY OPTIONS
MALE HORMONE THERAPY OPTIONS The following tables have been compiled by Women s staff pharmacists to represent some of the more frequently prescribed regimens for men. The Women s logo is placed throughout
More informationANNEX 3 TO THE DRAFT REPORT OF THE OECD VALIDATION OF THE RAT HERSHBERGER BIOASSAY: PHASE 2
ANNEX 3 TO THE DRAFT REPORT OF THE OECD VALIDATION OF THE RAT HERSHBERGER BIOASSAY: PHASE 2 Hershberger Assay Interlaboratory Study: Statistical analysis of phase 2 data from 16 laboratories in the multi-chemical
More informationHealth Products Regulatory Authority
1 NAME OF THE VETERINARY MEDICINAL PRODUCT Myodine 25 mg/ml solution for injection for dogs and cats 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains: Active substance: Nandrodine laurate 25
More informationTREATMENT OPTIONS FOR MALE HYPOGONADISM
TREATMENT OPTIONS FOR MALE HYPOGONADISM Bruce Biundo, RPh, FACA PCCA Pharmacy Consulting Department Updated July 2012 Hypogonadism in men is primarily a state involving lower than expected levels of testosterone,
More informationNutrition, supplements, and exercise
Nutrition, supplements, and exercise Walter R. Frontera, MD, PhD Professor and Chair Department of Physical Medicine and Rehabilitation Vanderbilt University School of Medicine And Medical Director of
More informationGrowth Hormone s Impact as a Safe Ergogenic Aid to Increase Body Size
Growth Hormone s Impact as a Safe Ergogenic Aid to Increase Body Size Point Argument: Growth Hormone is a Safe Ergogenic Aid to Increase Body Size Monica Chauhan Carissa Eastwood Emily Lefler Mar. 28,
More informationPRODUCT INFORMATION. Testosterone Phenylpropionate: Testosterone Phenylpropionate is 3-oxoandrost-4-en-17β-yl
PRODUCT INFORMATION SUSTANON '250' NAME OF THE MEDICINE Sustanon '250' ('250' mg/ml for injection): testosterone propionate, testosterone phenylpropionate, testosterone isocaproate, testosterone decanoate.
More informationThe Science of. NUTRICULA Longevity Journal
32 December, 2011 The Science of 33 NUTRICULA Longevity Journal As men age, there is often a decline in libido and sexual function. This decline frequently interferes in intimacy within romantic relationships,
More informationTestosterone Topical/Buccal/Nasal
BENEFIT APPLICATION Testosterone Topical/Buccal/Nasal DRUG POLICY Benefit determinations are based on the applicable contract language in effect at the time the services were rendered. Exclusions, limitations
More informationAdverse effects of anabolic androgenic steroids abuse on gonadal function, glucose homeostasis and cardiovascular function
Adverse effects of anabolic androgenic steroids abuse on gonadal function, glucose homeostasis and cardiovascular function Associate Professor Caroline Kistorp, Ph.D Department of Internal Medicine, Herlev
More informationJournal of Steroid Biochemistry and Molecular Biology
Journal of Steroid Biochemistry & Molecular Biology 117 (2009) 132 138 Contents lists available at ScienceDirect Journal of Steroid Biochemistry and Molecular Biology journal homepage: www.elsevier.com/locate/jsbmb
More informationTestosterone Effects in Transmen
Transmen Testosterone Effects in Transmen EFFECT Skin oiliness/acne Facial/body hair growth Scalp hair loss Increased muscle mass/strength Fat redistribution Cessation of menses Clitoral enlargement Vaginal
More informationMen with hypogonadism require testosterone replacement
Journal of Andrology, Vol. 24, No. 5, September/October 2003 Copyright American Society of Andrology Oral Testosterone-Triglyceride Conjugate in Rabbits: Single-Dose Pharmacokinetics and Comparison With
More informationRisks Versus Benefits of Testosterone Therapy in Elderly Men
REVIEW ARTICLE Drugs & Aging 1999 Aug; 15 (2): 131-142 1170-229X/99/0008-0131/$06.00/0 Adis International Limited. All rights reserved. Risks Versus Benefits of Testosterone Therapy in Elderly Men Shehzad
More informationMonitoring of performance an training in rowers
Monitoring of performance an training in rowers Jaak Jürimäe Demands of the Sport High maximal oxygen consumption (VO 2max ); Ability to perform at a high percentage of VO 2max for the duration of event;
More informationProgestagens Androgenic Action on the Bone of Male Castrated Mice
Prague Medical Report / Vol. 107 (2006) No. 4, p. 401 408 401) Progestagens Androgenic Action on the Bone of Male Castrated Mice Broulík P. D. 1, Broulíková K. 1, Nečas E. 2 1 Third Medical Department
More informationThe Testosterone Quandary. Beth Crowder, PhD, APRN
The Testosterone Quandary Beth Crowder, PhD, APRN Objectives Define testosterone, the hypothalamic-pituitary-gonadotrophic axis, and normal blood levels List functions of testosterone and symptoms of low
More informationPharmacodynamics of Selective Androgen Receptor Modulators (SARMs)
JPET Fast This Forward. article has not Published been copyedited on and December formatted. The 13, final 2002 version as may DOI:10.1124/jpet.102.040840 differ from this version. Pharmacodynamics of
More informationPerformance Enhancing Drugs in Sports
Performance Enhancing Drugs in Sports Mark D. Price, M.D., Ph.D Assistant Professor, Department of Orthopedic Surgery University of Massachusetts Medical School Historical Perspective 1889 Brown-Sequard
More informationAS our population ages, concerns about frailty and
Journal of Gerontology: MEDICAL SCIENCES 2004, Vol. 59A, No. 5, 461 465 Copyright 2004 by The Gerontological Society of America Special Article Masculine Vitality: Pros and Cons of Testosterone in Treating
More informationTestosterone ELISA Kit
Testosterone ELISA Kit Catalog Number KA3396 96 assays Version: 03 Intended for research use only www.abnova.com Table of Contents Introduction... 3 Background... 3 Principle of the Assay... 3 General
More informationEuropean Journal of Endocrinology (2009) ISSN
European Journal of Endocrinology (2009) 160 681 687 ISSN 0804-4643 CLINICAL STUDY Measures of bioavailable serum testosterone and estradiol and their relationships with muscle mass, muscle strength and
More informationThe importance of (dairy) protein for maintenance of muscle mass during aging & rehabilitation
The importance of (dairy) protein for maintenance of muscle mass during aging & rehabilitation METTE HANSEN, Associated Professor INSTITUTE OF PUBLIC HEALTH SECTION OF SPORT SCIENCE AARHUS DENMARK Kontakt@mettehansen.nu
More informationLEUCINE. - A major driving force for Muscle Protein Synthesis
LEUCINE - A major driving force for Muscle Protein Synthesis An article by Professor Don MacLaren, 2016. Leucine is one of the 9 essential amino acids that are required to be ingested by the body since
More informationAndrogenes and Antiandrogenes
Androgenes and Antiandrogenes Androgens The androgens are a group of steroids that have anabolic and/or masculinizing effects in both males and females. Testosterone [tess-toss-terone], the most important
More informationNew long-acting androgens
World J Urol (2003) 21: 306 310 DOI 10.1007/s00345-003-0364-x TOPIC PAPER Louis J. Gooren New long-acting androgens Received: 16 September 2003 / Accepted: 17 September 2003 / Published online: 9 October
More informationSue Marty, Ph.D., D.A.B.T. The Dow Chemical Company TERA Endocrine Workshop April 23, 2013
Sue Marty, Ph.D., D.A.B.T. The Dow Chemical Company TERA Endocrine Workshop April 23, 2013 Agenda Value of WoE/MoA determinations in EDSP Information used to examine potential endocrine activity and/or
More informationEffect of Maternal Drug Treatment during Pregnancy and Lactation Oxymetholone through the Levels of Sex Hormones in Adult Female Offspring Rats
Advances in Environmental Biology, 6(10): 2791-2795, 2012 ISSN 1995-0756 2791 This is a refereed journal and all articles are professionally screened and reviewed ORIGINAL ARTICLE Effect of Maternal Drug
More informationTestosterone Enanthate (Cas No ) Specification USP/BP. testosterone enanthate. Raw Material / Chemicals Index. Taj Pharmaceuticals Ltd.
Testosterone Enanthate (Cas No 315-37-7) Specification USP/BP Taj Active Pharmaceuticals Ingredients TAJCPG-DCYHEAPAZQ www.tajapi.com Raw Material / Chemicals Index Taj Pharmaceuticals Ltd. Testosterone
More informationThe Effects of Chronic Creatine Supplementation on Performance and Body Composition of Female Athletes. by Megan Brenner
The Effects of Chronic Creatine Supplementation on Performance and Body Composition of Female Athletes by Megan Brenner Thesis submitted to the Faculty of Virginia Polytechnic Institute and State University
More informationSkin metabolism of steroid hormones as endogenous compounds?
Skin metabolism of steroid hormones as endogenous compounds? Van Luu-The Department of Molecular Medicine Laval University Québec, Canada This work has been supported by L Oréal Research Steroid hormones
More informationMI Androgen Deficiency Hypogonadism
MI Androgen Deficiency Hypogonadism WADA TUE Expert Group John A Lombardo, MD October 2014, Columbus, Ohio USA Hypothalamic-Pituitary-Gonadal Axis / 2 Hypogonadism/Androgen Deficiency Clinical syndrome:
More informationCreatine Versus Anabolic Steroids. Over the past few years, many athletes have been using performance-enhancing
Hester 1 Kyle Hester Instructor s Name ENGL 1013 Date Creatine Versus Anabolic Steroids Over the past few years, many athletes have been using performance-enhancing supplements on a regular basis. Two
More informationSIMPLE, EFFICIENT AND SIMULTANEOUS DETERMINATION OF ANABOLIC STEROIDS IN HUMAN URINE
SIMPLE, EFFICIENT AND SIMULTANEOUS DETERMINATION OF ANABOLIC STEROIDS IN HUMAN URINE Pages with reference to book, From 216 To 218 S.J. Khurshid, M. Riaz, S. Ahmed ( Nuclear Chemistry Division, Pakistan
More informationHGH for Sale Human Growth Hormone
HGH for Sale Human Growth Hormone Many people consider HGH for sale, or Human Growth Hormone (C 990 H 1529 N 263 O 299 S 7 ) the fountain of youth. In fact, many experts suggest that this is the most sought-after
More informationMSD 96-Well MULTI-ARRAY and MULTI-SPOT Human Granulocyte Colony Stimulating Factor (hg-csf) Ultrasensitive Assay
MSD 96-Well MULTI-ARRAY and MULTI-SPOT Human Granulocyte Colony Stimulating Factor (hg-csf) Ultrasensitive Assay Summary This assay measures Human Granulocyte Colony Stimulating Factor (G-CSF) in a 96-well
More informationPharmacodynamics of Selective Androgen Receptor Modulators
0022-3565/03/3043-1334 1340$7.00 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS Vol. 304, No. 3 Copyright 2003 by The American Society for Pharmacology and Experimental Therapeutics 40840/1047711
More informationFormulating With Whey In A Fully Transparent Market. Chris Lockwood, PhD President May 22-23, 2018
Formulating With Whey In A Fully Transparent Market Chris Lockwood, PhD President May 22-23, 2018 Driving Protein Demand Only Major Nutrient That Stimulates Muscle Building (Muscle Protein Synthesis, or
More informationPRODUCT INFORMATION PRIMOTESTON DEPOT. (testosterone enantate)
PRODUCT INFORMATION PRIMOTESTON DEPOT (testosterone enantate) NAME OF THE MEDICINE Testosterone enantate is designated chemically as 17 beta-heptanoyloxy-4-androstene-3- one. The empirical formula of testosterone
More informationPHYSICIANS CIRCULAR FINASTERIDE PROSCAR. Tablet 5-Alpha Reductase Inhibitor
PHYSICIANS CIRCULAR FINASTERIDE PROSCAR Tablet 5-Alpha Reductase Inhibitor FINASTERIDE (PROSCAR) a synthetic 4-azasteroid compound, is a specific inhibitor of Type II 5α-reductase, an intracellular enzyme
More informationTestosterone and androstanediol glucuronide among men in NHANES III
Duan and Xu BMC Public Health (2018) 18:339 https://doi.org/10.1186/s12889-018-5255-6 RESEARCH ARTICLE Open Access Testosterone and androstanediol glucuronide among men in NHANES III Chuan Wei Duan 1 and
More informationDEPO-Testosterone Injection is available in two strengths, 100 mg/ml and 200 mg/ml testosterone cypionate.
Depo -Testosterone testosterone cypionate injection, USP CIII DESCRIPTION DEPO-Testosterone Injection, for intramuscular injection, contains testosterone cypionate which is the oil-soluble 17 (beta)- cyclopentylpropionate
More informationLaboratoires Dom AVMM (Suisse) Inc. New Innovation in Peptide Therapy for Slimming
Laboratoires Dom AVMM (Suisse) Inc New Innovation in Peptide Therapy for Slimming Globally, Fat Facts 1 billion overweight adults 300 million obese adults A major risk for chronic diseases: Type 2 diabetes
More informationLong-term experience with testosterone replacement through scrotal skin
CHAPTER 13 1 Long-term experience with testosterone replacement through scrotal skin Linda E. Atkinson, Yu-Lin Chang, and Peter J. Snyder Contents 13.1 13.1.1 13.1.2 13.2 13.2.1 13.2.2 13.2.2.1 13.2.2.2
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationAnavar For Sale Oxandrolone
Anavar For Sale Oxandrolone Anavar (oxandrolone C 19 H 30 O 3 ) is an anabolic steroid that provides outstanding results. The Anavar steroid is a synthesized version of testosterone that boosts lean muscle
More informationDr Chris Ward Manchester Royal Infirmary
Dr Chris Ward Manchester Royal Infirmary Overheard at the gym: a clinician s overview of interactions/toxicities of commonly used drugs: Non steroids Dr Chris Ward Consultant Genitourinary Medicine The
More informationTreatment of androgen deficiency in the aging male
Treatment of androgen deficiency in the aging male The Practice Committee of the American Society for Reproductive Medicine Birmingham, Alabama Although guidelines for androgen replacement therapy for
More informationThe Influence of Load Carrying Modes on Gait variables of Healthy Indian Women
The Influence of Load Carrying Modes on Gait variables of Healthy Indian Women *Guha Thakurta A, Iqbal R and De A National Institute of Industrial Engineering, Powai, Vihar Lake, Mumbai-400087, India,
More informationAntiduretic Hormone, Growth. Hormone & Anabolic Steroids
Goudarz Sadeghi, DVM, PhD, DSc Associate Professor of Pharmacology University of Tehran Faculty of Veterinary Medicine Veterinary Pharmacology Endocrine System Antiduretic Hormone, Growth Hormone & Anabolic
More informationStimulation of net muscle protein synthesis by whey protein ingestion before and after exercise
Am J Physiol Endocrinol Metab 292: E71 E76, 2007. First published August 8, 2006; doi:10.1152/ajpendo.00166.2006. Stimulation of net muscle protein synthesis by whey protein ingestion before and after
More informationUpdates on Anti-doping and TUE Management in Paralympic Sport
International Paralympic Committee Updates on Anti-doping and TUE Management in Paralympic Sport Matthew Fedoruk, Ph.D. March 15, 2018 PyeongChang 2018 IPC Medical / Sports Science Committee Workshops
More informationIcd-10 low levels of testosterone
Icd-10 low levels of testosterone The Borg System is 100 % Icd-10 low levels of testosterone 1-10-2017 if your hormone levels are too high or too low, you may have a hormone disorder. Hormone diseases
More informationHGH for Sale Natural Anti-Aging Human Growth Hormone
HGH for Sale Natural Anti-Aging Human Growth Hormone Human growth hormone is one of the hottest supplement trends on the market, and now you can purchase top-quality HGH to be delivered right to your home!
More informationClinical Policy: Testosterone Reference Number: AZ.CP.PHAR.02 Effective Date: Last Review Date: Line of Business: Arizona Medicaid
Clinical Policy: Reference Number: AZ.CP.PHAR.02 Effective Date: 11.16.16 Last Review Date: 09.12.18 Line of Business: Arizona Medicaid Revision Log See Important Reminder at the end of this policy for
More informationNatural Hair Transplant Medical Center, Inc Dove Street, Suite #250, Newport Beach, CA Phone
Natural Hair Transplant Medical Center, Inc. 1000 Dove Street, Suite #250, Newport Beach, CA 92660 Phone-949-622-6969 Finasteride (PROPECIA ) Acknowledgement Finasteride is an oral medication, manufactured
More informationFigure 2. RESULTS DATA ANALYSIS
ANDROGEN PARAMETERS IN HIRSUTE AND NORMAL FEMALE PATIENTS: IS THERE A ROLE FOR THE FREE ANDROGEN INDEX (FAI)? Castracane VD 1, Childress E 1, Tawwater B 1, Vankrieken L 2, El Shami AS 2 ( 1 Department
More informationClinical impact of type I and type II 5 alpha-reductase inhibition in prostatic disease: review and update 아주대학교김선일
Clinical impact of type I and type II 5 alpha-reductase inhibition in prostatic disease: review and update 아주대학교김선일 Development of 5ARI Discovery of 5AR type I and type II Pharmacodynamic and pharmacokinetic
More informationWVWCI BIGGEST LOSER WEEK 3: WALKING BASICS DRESS FOR SUCCESS
DRESS FOR SUCCESS Make sure you dress appropriately for walking. The following items will help you judge what to wear: Wear shoes with proper arch support, a firm heel, and thick, flexible soles that will
More informationMale pattern baldness is the most common type of balding among males. It affects roughly, 50% of men by the age of 50,
Dihydrotestosterone (DHT) Male pattern baldness is the most common type of balding among males. It affects roughly, 30% of men by the age of 30, 50% of men by the age of 50, 57% of men by the age of 60.
More informationCONFÉRENCE À SUCCÈS EN SCIENCES DE LA VIE : ENDOCEUTICS
CONFÉRENCE À SUCCÈS EN SCIENCES DE LA VIE : ENDOCEUTICS 13 Septembre 2018 Quebec, Canada 1 ENDOCEUTICS No. 1 Innovative pharmaceutical company in menopausal women s health in the world 2 Facilities Head
More information